Showing 731-740 of 797 results for "".
- Indirect Treatment Comparison Between Ingrezza and Austedo to Treat Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/indirect-treatment-comparison-between-ingrezza-and-autesto-to-treat-chorea-associated-with-huntington-disease/2470278/Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) may provide more benefit in early treatment of chorea symptoms associated with Huntington disease (HD) than Austedo (deutetrabenazine; Teva Pharmaceuticals, Tel Aviv, Israel), according to results of a study presented at the 2023 Inter
- Ingrezza Approved for the Treatment of Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/ingrezza-approved-for-the-treatment-of-chorea-associated-with-huntington-disease/2470271/Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) has received approval from the Food and Drug Administration (FDA) for the treatment of adults with chorea associated with Huntington disease (HD). The agent, del
- FDA Grants Orphan Drug Designation to Exon 44 Skipping AOC for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-orphan-drug-designation-to-exon-44-skipping-aoc-for-duchenne-muscular-dystrophy/2470270/AOC 1044 (Avidity Biosciences, San Diego, CA), an antibody oligonucleotide conjugate (AOC), was granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with Duchenne muscular
- Full Results from LAVENDER Study Confirm Benefits of Daybue to Treat Rett Syndrome Symptomshttps://practicalneurology.com/news/full-results-from-lavender-study-confirm-benefits-of-daybue-to-treat-rett-syndrome-symptoms/2470208/According to new results of the LAVENDER study published in Nature Medicine, Daybue (trofinetide, Acadia Pharmaceuticals Inc., San Diego, CA) may be effective in treating and improving core symptoms of Rett syndrome
- FDA Grants Fast Track Designation for Antibody Oligonucleotide Conjugate to Treat Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-fast-track-designation-for-antibody-oligonucleotide-conjugate-to-treat-duchenne-muscular-dystrophy/2470170/AOC 1044 (Avidity Biosciences, Inc, San Diego, CA), a drug in the new class of RNA therapeutics called antibody oligonucleotide conjugates (AOCs), was granted Fast Track designation by the Food and Drug Administration (FDA)
- New Therapy Approved for Rett Syndromehttps://practicalneurology.com/news/new-therapy-approved-for-rett-syndrome/2470139/The Food and Drug Administration (FDA) has approved trofinetide (Daybue; Acadia Pharmaceuticals, San Diego, CA) for the treatment of
- Pimavanserin Lowers Mortality Risk in Those with Parkinson Disease Psychosishttps://practicalneurology.com/news/pimavanserin-lowers-mortality-risk-in-those-with-parkinson-disease-psychosis/2470091/Results from a retrospective analysis published in Drug Safety indicate that individuals with Parkinson disease psychosis (PDP) treated with pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) have a lower mortality risk compared with those treated with other atypical an
- New FDA Filing for Potential Drug To Treat Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/new-fda-filing-for-potential-drug-to-treat-chorea-associated-with-huntington-disease/2470090/The Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) as a treatment for chorea associated with Huntington disease (HD). The sNDA filing contained data from the KINECT-HD phase 3 study (
- Opicapone Evaluated for Patient Characteristics, Treatment Patterns, and Safety/Tolerability in Individuals with Parkinson Diseasehttps://practicalneurology.com/news/opicapone-evaluated-for-patient-characteristics-treatment-patterns-and-safetytolerability-in-individuals-with-parkinson-disease/2470060/In the Opicapone Treatment Initiation Open-Label Study (OPTI-ON) study, participants treated with opicapone (Ongentys; Neurocrine Biosciences, San Diego, CA) for Parkinson disease (PD) "OFF" episodes were observed for patient characteristics, treatment patterns, and safety/tolerability.
- FDA Accepts New Drug Application of Trofinetide for Rett Syndrome Treatmenthttps://practicalneurology.com/news/fda-accepts-new-drug-application-of-trofinetide-for-rett-syndrome-treatment/2470018/The Food and Drug Administration (FDA) has accepted filing of a New Drug Application (NDA) for trofinetide (Acadia Pharmaceuticals, San Diego, CA) for the treatment of Rett syndrome. Support for the application comes from the pivotal phase 3 Lavender study (NCT04181723), the results of which were